Dr. Kathleen J. Yost
Claim this profileBronson Methodist Hospital
Expert in Cancer
Expert in Thyroid Cancer
233 reported clinical trials
343 drugs studied
Area of expertise
1Cancer
Global LeaderStage IV
Stage I
Stage II
2Thyroid Cancer
Global LeaderStage IV
Stage III
Stage I
Affiliated Hospitals
Clinical Trials Kathleen J. Yost is currently running
Selumetinib vs. Chemotherapy
for Brain Cancer
This trial is comparing a new drug, selumetinib, with standard chemotherapy to treat patients with a specific type of brain tumor. The patients do not have a certain genetic mutation and are not affected by a genetic disorder. Selumetinib works by blocking enzymes needed for tumor growth, while the standard drugs kill or stop tumor cells from dividing.
Recruiting2 awards Phase 3
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting2 awards Phase 3
More about Kathleen J. Yost
Clinical Trial Related7 years of experience running clinical trials · Led 233 trials as a Principal Investigator · 104 Active Clinical TrialsTreatments Kathleen J. Yost has experience with
- Cisplatin
- Nivolumab
- Carboplatin
- Radiation Therapy
- Pembrolizumab
- Cyclophosphamide
Breakdown of trials Kathleen J. Yost has run
Cancer
Thyroid Cancer
Uterine Tumors
Breast Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Kathleen J. Yost specialize in?
Kathleen J. Yost focuses on Cancer and Thyroid Cancer. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage I.
Is Kathleen J. Yost currently recruiting for clinical trials?
Yes, Kathleen J. Yost is currently recruiting for 97 clinical trials in Kalamazoo Michigan. If you're interested in participating, you should apply.
Are there any treatments that Kathleen J. Yost has studied deeply?
Yes, Kathleen J. Yost has studied treatments such as Cisplatin, Nivolumab, Carboplatin.
What is the best way to schedule an appointment with Kathleen J. Yost?
Apply for one of the trials that Kathleen J. Yost is conducting.
What is the office address of Kathleen J. Yost?
The office of Kathleen J. Yost is located at: Bronson Methodist Hospital, Kalamazoo, Michigan 49007 United States. This is the address for their practice at the Bronson Methodist Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.